TRILACICLIB
Total Payments
$280,771
Transactions
90
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $280,771 | 90 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $280,771 | 90 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TRILACICLIB IN PATIENTS RECEIVING SACITUZUMAB GOVITECAN-HZIY FOR TRIPLE NEGATIVE BREAST CANCER | Pharmacosmos Therapeutics Inc. | $279,778 | 0 |
| TRILACICLIB, A CDK 4/6 INHIBITOR, IN PATIENTS RECEIVING FOLFOXIRI/BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER (MCRC): (PRESERVE1) | Pharmacosmos Therapeutics Inc. | $993.40 | 0 |
Top Doctors Receiving Payments for TRILACICLIB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Puyallup, WA | $280,771 | 90 |
Ad
Manufacturing Companies
- Pharmacosmos Therapeutics Inc. $280,771
Product Information
- Type Drug
- Total Payments $280,771
- Total Doctors 0
- Transactions 90
About TRILACICLIB
TRILACICLIB is a drug associated with $280,771 in payments to 0 healthcare providers, recorded across 90 transactions in the CMS Open Payments database. The primary manufacturer is Pharmacosmos Therapeutics Inc..
Payment data is available from 2024 to 2024. In 2024, $280,771 was paid across 90 transactions to 0 doctors.
The most common payment nature for TRILACICLIB is "Unspecified" ($280,771, 100.0% of total).
TRILACICLIB is associated with 2 research studies, including "TRILACICLIB IN PATIENTS RECEIVING SACITUZUMAB GOVITECAN-HZIY FOR TRIPLE NEGATIVE BREAST CANCER" ($279,778).